How cartilage protects itself — and why that protection fails

Inside every joint, a quiet defence is operating. Most people are unaware it exists until it has already begun to fail.

Research published in Nature Communications in 2026 identified a protein called SHP as a critical natural defender of cartilage. Understanding how it works — and why it declines — changes the conversation about when and how to protect joint health.

What SHP does

SHP (technically known as NR0B2) suppresses a signalling pathway called IKKβ/NF-κB. When this pathway is active, it drives production of two enzymes — MMP-3 and MMP-13 — that physically break down the cartilage matrix. Type II collagen, the structural backbone of cartilage, is among their targets.

In a healthy joint, SHP keeps this pathway quiet. MMP-3 and MMP-13 remain suppressed. Cartilage structure is maintained.

Why it fails

In osteoarthritis patients, SHP levels decline as the disease progresses. The research demonstrated this across both human cartilage tissue and animal models. Mice bred without SHP developed more severe joint damage and experienced faster cartilage breakdown than normal mice. When SHP was restored through gene delivery, cartilage damage reduced and joint function improved — even in animals that already had established osteoarthritis.

The lead investigator described it as the first demonstration that SHP plays a critical role in protecting cartilage during the development and progression of osteoarthritis.

The gut connection

SHP decline is not isolated to the joint. The IKKβ/NF-κB pathway that SHP suppresses is also activated by bacterial byproducts called lipopolysaccharides — which enter the bloodstream when the gut barrier is compromised.

When gut bacteria fall out of balance, the intestinal lining can become more permeable. LPS passes through, enters circulation, and activates NF-κB systemically. In joint tissue, this suppresses SHP and triggers the enzyme cascade that destroys cartilage.

The gut is upstream of this process. Gut health influences SHP. SHP influences cartilage integrity.

The window before diagnosis

This is where the research becomes most significant for most people.

SHP levels do not suddenly drop when osteoarthritis is diagnosed. They decline gradually as the disease develops — meaning the protection is eroding long before symptoms become severe enough to warrant investigation. By the time a GP refers a patient for imaging, the window for upstream intervention may already be narrowing.

For the person who notices stiffness after sitting, slower recovery, joints that feel different from how they used to feel — this research identifies a biological mechanism that is likely already changing. Conventional medicine has nothing to offer that person. There is no drug, no supplement, no clinical protocol that targets SHP or the conditions that sustain it, available to a patient in the preventive window.

What the research points toward

Several plant-derived compounds have published evidence for inhibiting IKKβ/NF-κB — the pathway SHP suppresses. Boswellic acids from Boswellia serrata are among the most specifically studied. Curcumin, EGCG from green tea, and quercetin each have relevant published evidence. Supporting gut barrier integrity — reducing the LPS translocation that activates NF-κB in the first place — represents an upstream approach.

None of this is treatment for osteoarthritis. It is biology — the same biology now identified in peer-reviewed research as the mechanism by which cartilage protects itself, and by which that protection is lost.

Further reading

Kang et al. (2026). SHP protects against osteoarthritis by inhibiting IKKβ/NF-κB-mediated matrix-degrading enzymes in chondrocytes. Nature Communications.

Yang et al. (2025). Gut microbiota–bile acid–GLP-1 axis in osteoarthritis. Science. doi:10.1126/science.adt0548

LYVA Flex is formulated around the biology described in this article. Read the full science or join the waitlist for founding member pricing.

— William Tyler-Street, Founder